American Association of Individual Investors1d
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Up 12.53%
Atara Biotherapeutics, Inc.’s ATRA share price has surged by 12.53%, which has investors questioning if this is right time to ...
Yahoo Finance21d
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after ... EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients undergo ...
Yahoo Finance20d
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued ... EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients ...
Atara Biotherapeutics: Workforce Reductions and Regulatory Challenges Lead to Hold Rating
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on January 21.Invest with ...
Reuters22d
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' (ATRA.O), opens new tab therapy to treat patients with a rare cancer that develops ...
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
ascopubs.org11d
Randomized study to assess colonic microbiome changes in response to energy drink consumption (ROSANNA Trial).
Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer. A phase 3 study of first-line ...
Business Wire22d
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO TM (tabelecleucel)
ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune ...